Due to the inconspicuous symptoms and rapid progression of HCC, most patients are diagnosed at an advanced stage, making systemic treatment especially important in the clinic.5 Unfortunately, the most prevalent oncogenic mutations are currently undruggable, such as mutations of TP53, CTNNB1 and the TERT promoter, and few molecular targeted therapies have proven to be effective.6,7 HCC is a typical solid tumor with abundant blood vessels. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.